Bristol-Myers (BMY) Licenses BioNTech’s Immunotherapy in $11 billion Deal

On Monday, June 2, Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing agreement focused on next-generation...

Keep Reading →